


APPENDIX A

This claim set replaces all previous claims in this application.

1. (Original) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and:
 - (a) an inhibitor of the RSV fusion protein; and
 - (b) a benzodiazepine derivative capable of inhibiting RSV replication.
2. (Original) A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,



wherein:

R^1 represents C_{1-6} alkyl, aryl or heteroaryl;

R^2 represents hydrogen or C_{1-6} alkyl;

each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, $-CO_2R'$, $-CONR'R''$, $-NH-CO-R'$, $-S(O)R'$, $-S(O)_2R'$, $-NH-S(O)_2R'$, $-S(O)NR'R''$ or $-S(O)_2NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;

n is from 0 to 3;

R^4 represents hydrogen or C_{1-6} alkyl;

X represents $-CO-$, $-CO-NR'-$, $-S(O)-$ or $-S(O)_2-$, wherein R' is hydrogen or a C_{1-6} alkyl group; and


R^5 represents an aryl, heteroaryl or heterocyclyl group which is substituted by a C_{1-6} hydroxyalkyl group or a $-(C_{1-4} \text{ alkyl})-X_1-(C_{1-4} \text{ alkyl})-X_2-(C_{1-4} \text{ alkyl})$ group, wherein X_1 represents $-O-$, $-S-$ or $-NR'-$, wherein R' represents H or a C_{1-4} alkyl group and X_2 represents $-CO-$, $-SO-$ or $-SO_2-$, or R^5 represents $-A_1-Y-A_2$, wherein:

A_1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group;

Y represents a direct bond or a C₁₋₆ alkylene, -SO₂-, -CO-, -O-, -S- or -NR'- moiety, wherein R' is a C₁₋₆ alkyl group; and A₂ is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.

3. (Previously presented) A composition according to claim 2 wherein R¹ is C₁₋₂ alkyl or phenyl.
4. (Previously presented) A composition according to claim 2, wherein R² is hydrogen.
5. (Withdrawn) A composition according to claim 2 wherein R³ is halogen, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, amino, mono(C₁₋₄ alkyl)amino or di(C₁₋₄ alkyl)amino.
6. (Withdrawn) A composition according to claim 5 wherein R³ is fluorine, chlorine, bromine, C₁₋₂ alkyl, C₁₋₂ alkoxy, C₁₋₂ alkylthio, C₁₋₂ haloalkyl, C₁₋₂ haloalkoxy, amino, mono(C₁₋₂ alkyl)amino or di (C₁₋₂ alkyl)amino.
7. (Previously presented) A composition according to claim 2, wherein R⁴ is hydrogen or C₁₋₂ alkyl.
8. (Previously presented) A composition according to claim 2, wherein X is -CO- or -CO-NR'- wherein R' represents hydrogen or a C₁₋₂ alkyl group.
9. (Withdrawn) A composition according to claim 2, wherein R⁵ is a 5- or 6- membered heterocyclyl, aryl or heteroaryl ring which is substituted by a C₁₋₆ hydroxyalkyl group or a -(C₁₋₄ alkyl)-X₁-(C₁₋₄ alkyl)-X₂-(C₁₋₄ alkyl) group, wherein X₁ and X₂ are as defined in claim 2.
10. (Withdrawn) A composition according to claim 9, wherein R⁵ is a 5- or 6- membered heteroaryl group which is substituted by a -CH₂-OH or -(C₁₋₄ alkyl)-NR'-(C₁₋₄ alkyl)-S(O)₂-(C₁₋₄ alkyl) substituent, wherein R' is hydrogen or C₁₋₂ alkyl.
11. (Previously presented) A composition according to claim 2, wherein A₁ is an aryl or heteroaryl group.

12. (Original) A composition according to claim 11, wherein A_1 is a phenyl group, a monocyclic 5- or 6- membered heteroaryl group or a 5- to 6- membered heteroaryl group fused to a monocyclic oxo-substituted 5- to 6- membered heterocyclyl group.
13. (Previously presented) A composition according to claim 2 wherein A_1 is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, nitro, C_{1-4} alkyl, C_{1-4} haloalkyl and C_{1-4} alkoxy substituents.
14. (Previously presented) A composition according to claim 2, wherein Y represents a direct bond, a C_{1-2} alkylene group, $-SO_2-$ or $-O-$.
15. (Previously presented) A composition according to claim 2 wherein A_2 is a phenyl, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl or C_{3-6} cycloalkyl group.
16. (Withdrawn) A composition according to claim 2, wherein when A_2 is a heterocyclyl group it is attached to the moiety Y via a N atom.
17. (Previously presented) A composition according to claim 2, wherein A_2 is unsubstituted or is substituted by 1 or 2 substituents which are selected from C_{1-4} alkyl and halogen substituents when A_2 is a heteroaryl or aryl group and which are selected from C_{1-4} alkyl, halogen and oxo substituents when A_2 is a carbocyclic or heterocyclyl group.
18. (Previously presented) A composition according to claim 2, wherein A_2 is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C_{1-2} alkyl group.
19. (Previously presented) A composition according to claim 2 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula (Va):



wherein:

X is -CO- or -CO-NH-; and

R⁵ is a 5- to 6-membered heteroaryl group, for example a furanyl group, which is substituted by -CH₂-OH or -(C₁₋₄ alkyl)-N(CH₃)-(C₁₋₄ alkyl)-SO₂-(C₁₋₄ alkyl) or R⁵ represents -A₁-Y-A₂, wherein:

A₁ is a phenyl, pyridyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, thienyl or 1H-imidazo[4,5-b]pyridin-2-(3H)-one moiety, which is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₂ alkoxy substituents;

Y is a direct bond, a C₁₋₂ alkylene group, -SO₂- or -O-; and

A₂ is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C₁₋₂ alkyl group.

20. (Original) A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is:

6-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-4-fluoro-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Chloro-2-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-5-fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-(4-Methyl-piperazin-1-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Pyrrolidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Piperidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Dimethylaminomethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide;

(S)-4-Fluoro-2-morpholino-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-piperidine-1-yl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-4-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-2-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-4-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-6-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-3-Cyclopropyl-2-oxo-2,3-dihydro-imidazo[4,5-b]pyridine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-(4-Methyl-piperazine-1-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-4-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(piperidine-1-sulfonyl)-benzamide;

(S)-3-(Morpholine-4-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-furan-2-carboxylic acid(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Hydroxymethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-(1,1-Dioxo-1λ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Chloro-4-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-5-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-[(2-Methanesulfonyl-ethyl)-methyl-amino]-methyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Pyridin-3-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Pyridin-4-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Methyl-2-pyrazin-2-yl-thiazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Morpholin-4-ylmethyl-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-isoxazole-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Pyridin-2-yl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Methyl-4-(morpholin-4-sulfonyl)-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-3-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Phenyl-oxazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-phenoxy-phenyl)-urea


an N-oxide of any of the above compounds;

or a pharmaceutically acceptable salt thereof.

21. (Withdrawn) A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is (S)-5-(1,1-Dioxo-1 λ 6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide or (S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide or a pharmaceutically acceptable salt thereof.

22. (Withdrawn) A composition according to claim 21, wherein the benzodiazepine derivative of formula (V) is (S)-5-(1, 1-Dioxo- 1 λ 6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide or a pharmaceutically acceptable salt thereof.

23. (Previously presented) A composition according to claim 1 wherein component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I)



wherein:

X is H or C₁₋₆ alkyl; said C₁₋₆ alkyl being optionally substituted with halogen, OCOR₄ or S(O)_n- C₁₋₆ alkyl;

Y is R₄, NR₄R₅, NCOR₄, =N-OR₄, -CONHR₄, COOR₄, -OR₄, aryl, heteroaryl, cyclyl or heterocyclyl, where R₄ and R₅ are H or C₁₋₆ alkyl;

Z is CR₆R₇, where R₆ and R₇ are independently H, or straight, branched or cyclic C₁₋₆ alkyl;

n is 1-6;

R₁ is CONR₄R₅, CO₂R₄ or C₁₋₆ alkyl, said C₁₋₆ alkyl can be optionally substituted with OR₄ or NR₈R₉;


R₈ and R₉ are each independently H, C₁₋₆ alkyl, SO₂R₅, CO₂R₄ or COR₄;

R₂ is selected from the group consisting of NH₂, CONR₆R₇, heteroaryl, C₂₋₆ alkenyl, CO₂R₄, N=CPh₂, C(=NH)NH₂ and C₁₋₆ alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, NR₁₀R₁₁, OSO₂R₄ and OR₄; R₉ and R₁₀ are

each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆cycloalkyl, CO₂R₄, COR₄ and SO₂R₄;

R₃ is selected from the group consisting of (1) CO₂R₉; (2) C₁₋₆ alkyl optionally substituted with CN, OR₄ or NR₆R₇; and (3) C₂₋₆ alkenyl substituted with CN;


Q is a member selected from the group consisting of



A is C or N, optionally substituted with H, halogen, straight, branched or cyclic C₁₋₆ alkyl, C₂₋₆ alkenyl, CO₂R₄, aryl or C₃₋₆ cycloalkyl wherein when A is carbon, it may also be optionally substituted by O or S via a double bond;


B is C or N; wherein when B is C it may be optionally substituted by H, C₁₋₆ alkyl, NO₂, CN, halogen, COR₄, COOR₄, CONHR₄C(=NH)NH₂ or C(=NOH)NH₂.

24. (Original) A composition according to claim 23 wherein component (a) is a compound of general formula (I), as defined above, or a pharmaceutically acceptable salt thereof, wherein at least two of R₁, R₂ and R₃ are hydrogen, and the other is hydrogen or -C(NH)-NH₂ and/or -X- Y is H, or X is a C₁₋₆ alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'R'', -COR', -SO₂R' or phenyl, wherein R' and R'' are the same or different and represent a C₁₋₆ alkyl group and/or Z is -CH₂- and/or Q is a moiety



wherein B is -CH- or -N-, A₁ is -C(O)- or -NH- and A₂ is -CH₂-, -CHR'- or -NR''-, wherein R' is a halogen atom and R'' represents a hydrogen atom or a C₁₋₄ alkyl, C₂₋₄ alkenyl, C₃₋₆ cycloalkyl, -SO₂-(C₁₋₆ alkyl), -SO₂-N(C₁₋₆ alkyl)₂ or -(CO-NH)_a-(C₁₋₄ alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.

25. (Withdrawn) A composition according to claim 1 wherein component (a) is a compound of formula (II), or a pharmaceutically acceptable salt thereof,



wherein:

L_1 is $-\text{CH}_2-$ or $-\text{CHR}_2-\text{CO}-$;

each X is the same or different and CH or N;

each R_1 is the same or different and is C_{1-6} alkyl, halogen, hydroxy, phenyl or

$(\text{CH}_2)_m=\text{NH}_2$;

n is 1 or 2;

R_2 is C_{1-6} alkoxy or C_{1-6} alkoxy-phenyl;

R_3 is C_{1-6} alkyl;

L_2 is $-\text{CH}_2-$ or $-\text{NH}-$;

Y is C_{1-6} alkyl or C_{1-6} alkenyl;

Z is H, $\text{N}(\text{R}_4)_2$, $-\text{C}(=\text{O})-\text{R}_5$, $-\text{C}(=\text{CH}_2)-\text{R}_5$, $-\text{CH}(\text{OH})-\text{R}_5$, $-\text{CH}(\text{CH}_3)-\text{R}_5$, $-\text{CH}(\text{OCH}_3)-\text{R}_5$;

each R_4 is the same or different and is H, C_{1-6} alkyl;

R_5 is C_{1-6} alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl;

and m = 1-6.

26. (Previously presented) A composition according to claim 1, wherein component (a) is:

1-Cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one

{2-[2-(1,2-Dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]ethyl}-diethyl-amine

{2-[2-(3-Iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine

1-Isopropenyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-(4-Hydroxy-benzyl)-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Isopropenyl-3-[1-(3-oxo-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(2-hydroxy-2-phenyl-ethyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

7-[2-(3-Isopropenyl-2-oxo-2,3-dihydrobenzoimidazol-1-ylmethyl)-benzoimidazol-1-yl]-heptanenitril

5-{3-[1-(3-Methanesulfonyl-propyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-yl}-pentanenitrile

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-carboxylic acid benzylamide

1-Methanesulfonyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-sulfonic acid dimethylamide

1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one

Bis(5-amidino-2-benzimidazolyl)-methane

2-{2-[1-[1-(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl]}-6-methyl-pyridin-3-ol

or a pharmaceutically acceptable salt thereof.

27. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, {2-[2-(1,2-dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]}ethyl}-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]}ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof.

28. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-

c]pyridin-2-one or 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydroimidazo[4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.

29. (Previously presented) A composition according to claim 1 wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.

30. (Previously presented) A composition according to claim 1 wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.

31. (Previously presented) A composition according to claim 1, for use in the treatment of the human or animal body.

32. (Previously presented) Use of: (a) an RSV fusion protein inhibitor as defined in claim 1; and (b) a benzodiazepine derivative defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection.

33. (Previously presented) Use according to claim 32, wherein component (a) is present in an amount of from 0.025 wt% to 10 wt% and component (b) is present in an amount of 0.025 wt% to 10 wt%.

34. (Previously presented) A product comprising: (a) an RSV fusion protein inhibitor as defined in claim 1; and (b) a benzodiazepine derivative as defined in claim 1; for separate, simultaneous or sequential use in the treatment of the human or animal body.

35. (Original) A product according to claim 34 for separate, simultaneous or sequential use in treating or preventing an RSV infection.

36. (Previously presented) A method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of: (a) an RSV fusion protein inhibitor as defined in claim 1; and (b) a benzodiazepine derivative as defined in claim 1.

37. (Previously presented) Use of an RSV fusion protein inhibitor as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in claim 1.

38. (Previously presented) Use of a benzodiazepine derivative as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with an RSV fusion protein inhibitor as defined in claim 1.